.avif)
A comprehensive update for IP professionals working in the life sciences.
Few sectors play for higher stakes than pharmaceuticals and next-gen agriculture and nowhere is the pressure greater than in securing and extending patent exclusivity.
Over the last 18 months, the European landscape for Supplementary Protection Certificates (SPCs) and Patent Term Extensions (PTEs) has shifted dramatically. For those responsible for global portfolios, these changes will have an immediate and significant impact.
This is why we are hosting a series of interactive, in person seminars exploring the latest developments within the European SPC framework including:
- Update on recent case law
- Strategies for protecting combinations of A and B
- SPCs for prodrugs
- The proposed reforms to regulatory exclusivities from the European Parliament and Council
- The SPC manufacturing waiver
- We also hope to have a US attorney with us to share related insights into biosimilars in the US system
.jpg)
